Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (. CR) translating into longer PFS need to be achieved. | Rationale and design of the Germanspeaking myeloma multicenter group GMMG trial HD6 A randomized phase III trial on the effect of elotuzumab in VRD induction consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma